Tags : Profound Medical

Profound Medical’s TULSA-PRO Receives the US FDA’s 510(k) Clearance for

Shots: The FDA’s 510 (k) clearance is based on TACT clinical study involves assessing of TULSA-PRO in 115 patients with biopsy-proven, organ-confined prostate cancer and has received primary treatment of whole-gland prostate ablation with sparing of the urethra and urinary sphincter across the US, Canada and Europe The TACT clinical study resulted in meeting its […]Read More